ArticleNPJ biofilms and microbiomes2025
Genomic insights and metabolic profiling of gut commensal Luoshenia tenuis at strain level.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Luoshenia tenuis, a newly identified gut commensal microbe from the family Christensenellaceae, has shown therapeutic effects on weight control and metabolic disorders in model mice. Bacterial strains are essential for investigations on the host-microbe interaction and further development of medical applications. In this study, we collected 27 strains of L. tenuis from the Christensenellaceae Gut Microbial Biobank (ChrisGMB) and sequenced their complete genomes. Our analysis revealed considerable genetic diversity and genomic plasticity. Metabolic prediction indicated that L. tenuis had a preference for metabolizing plant-derived carbohydrates and the ability to synthesize various amino acids and cofactors. In silico analysis, along with in vitro experiments, validated that L. tenuis strains possessed strong acid tolerance and limited antibiotic resistance, suitable traits for oral probiotic development. Further volatile metabolomics and bile acid transformation profiling revealed that L. tenuis was capable of producing metabolites with previously-identified beneficial effects, along with extensive bile acid modification, potentially contributing to its positive impact on host metabolism. This study provides essential insight into strain-level functional and genomic features, laying a foundation for future research towards the development of L. tenuis-based therapies for metabolic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.